Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case report
- Authors:
- Yanhua Li
- Qiang Xu
- Xinhong Guo
View Affiliations
Affiliations: Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China
- Published online on: June 8, 2016 https://doi.org/10.3892/etm.2016.3439
-
Pages:
1177-1180
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
A 68-year-old man presented with acute coronary syndrome (ACS). The glycoprotein/IIb/IIIa receptor antagonist tirofiban was administered to the patient to treat a right coronary artery slow flow detected during percutaneous coronary intervention. The patient developed very severe thrombocytopenia 8 h after tirofiban infusion with no signs of bleeding. Antiplatelet medication was discontinued immediately, methylprednisolone was administered and platelets were transfused. Thrombopoietin (TPO) was also applied to the patient as recommended by a hematology consultant. As a result, the patient had in‑stent thrombosis and cerebral infarction, then another sirolimus‑eluting stent was implanted in the proximal right coronary artery and intensive anti‑platelet as well as intermittent dehydration to reduce intracranial pressure, and protection of the nervous system function treatment was also provided. The patient was left with a decreased muscle strength in the right limb muscle and fine movement disorder, which may have lead to a poor prognosis. To the best of our knowledge, this is the first case report of tirofiban‑induced severe thrombocytopenia with secondary in‑stent thrombosis and cerebral infarction from China. The experience of the diagnosis and treatment of this case may shed some light on the clinical use of TPO in tirofiban-induced thrombocytopenia.
View References
|
1
|
Dasgupta H, Blankenship JC, Wood GC, Frey
CM, Demko SL and Menapace FJ: Thrombocytopenia complicating
treatment with intravenous glycoprotein IIb/IIIa receptor
inhibitors: A pooled analysis. Am Heart J. 140:206–211. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yeung J and Holinstat M: Newer agents in
antiplatelet therapy: A review. J Blood Med. 3:33–42.
2012.PubMed/NCBI
|
|
3
|
Labinaz M, Ho C, Banerjee S, Martin J,
Chen S and Mensinkai S: Meta-analysis of clinical efficacy and
bleeding risk with intravenous glycoprotein IIb/IIIa antagonists
for percutaneous coronary intervention. Can J Cardiol. 23:963–970.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li B, Ji Y, Shao Q, Zhu Z, Ji D, Li F and
Chen G: Comparative efficacy and cost effectiveness of splenectomy
and thrombopoietin prior to peginterferon and ribavirin therapy
with compensatory cirrhosis associated with hepatitis C and
thrombocytopenia. Exp Ther Med. 10:2180–2186. 2015.PubMed/NCBI
|
|
5
|
Gudbrandsdottir S, Frederiksen H, Birgens
HS, Nielsen CH, Nielsen OJ, Stentoft J and Hasselbalch HC: New
treatment options for primary immune thrombocytopenia. Ugeskr
Laeger. 173:271–274. 2011.(In Danish). PubMed/NCBI
|
|
6
|
Yuan SM: Report: Heparin-induced
thrombocytopenia associated with cardiopulmonary bypass:
Preliminary attempt with recombinant human thrombopoietin therapy.
Pak J Pharm Sci. 28:1793–1796. 2015.PubMed/NCBI
|
|
7
|
Tuhta AG, Yeşildağ O and Köprülü D:
Tirofiban-associated acute thrombocytopenia. Acta Cardiol.
61:577–579. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuter DJ: The biology of thrombopoietin
and thrombopoietin receptor agonists. Int J Hematol. 98:10–23.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huxtable LM, Tafreshi MJ and Rakkar AN:
Frequency and management of thrombocytopenia with the glycoprotein
IIb/IIIa receptor antagonists. Am J Cardiol. 97:426–429. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuter DJ: Thrombopoietin: Biology and
clinical applications. Oncologist. 1:98–106. 1996.PubMed/NCBI
|
|
11
|
Aster RH: Immune thrombocytopenia caused
by glycoprotein IIb/IIIa inhibitors. Chest. 127(2 Suppl): 53S–59S.
2005. View Article : Google Scholar : PubMed/NCBI
|
